Clinical Characteristics and Outcomes of COVID-19 in 1294 New Cancer Patients: Single-Center, Prospective Cohort Study from Iran.


Journal

Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154

Informations de publication

Date de publication:
Jul 2022
Historique:
pubmed: 7 5 2022
medline: 18 6 2022
entrez: 6 5 2022
Statut: ppublish

Résumé

To determine the clinical characteristics and outcomes of COVID-19 in a large cohort of new cancer patients referred to an oncology clinic in the north of Iran. During the 20-month COVID-19 pandemic, new cancer patients were followed-up. Demographic, pathologic, and clinical variables were collected for each patient. COVID-19 was confirmed based on a positive polymerase chain reaction test. Analyses were performed using the STATA version 14.0 at a significance level of 0.05. In this study, 1294 new cancer patients were followed for 24 months (mean age: 58.7 years [range 10-95]). During the study period, COVID-19 was diagnosed in 9.4% of the patients with hospitalization rate of 3.4%, an ICU admission rate of 0.7%, and COVID-19 mortality rate of 4.9%. Hematological malignancies (OR In patients suffering from cancer, COVID-19 infection can be predicted by cancer type, palliative care, and radiotherapy in cancer patients. Furthermore, brain cancers, metastasis, and palliative care were all associated with COVID-19-related mortality.

Identifiants

pubmed: 35521692
doi: 10.1080/07357907.2022.2075376
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-515

Auteurs

Danial Fazilat-Panah (D)

Cancer Research Center, Babol University of Medical Sciences, Babol, Iran.

Hamid Fallah Tafti (H)

Resident of Radiation Oncology, Babol University of Medical Sciences, Babol, Iran.

Yavar Rajabzadeh (Y)

Babolsar Rajaee Cancer Center, Babol University of Medical Sciences, Babol, Iran.

Maedeh Alsadat Fatemi (MA)

Cancer Research Center, Babol University of Medical Sciences, Babol, Iran.

Nahid Ahmadi (N)

Cancer Research Center, Babol University of Medical Sciences, Babol, Iran.

Davoud Jahansouz (D)

Babolsar Rajaee Cancer Center, Babol University of Medical Sciences, Babol, Iran.

Mohsen Tabasi (M)

Center for Inflammation and Lung Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.

Seyed Alireza Javadinia (SA)

Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Maryam Joudi (M)

Department of Pediatrics, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran.

Hadi Harati (H)

Pediatric Gastroenterology and Hepatology Research Center, Zabol University of Medical Sciences, Zabol, Iran.

Fahimeh Attarian (F)

Department of Public Health, School of Health, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.

Farzad Taghizadeh-Hesary (F)

Radiation Oncology Department, Iran University of Medical Sciences, Tehran, Iran.
ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, Hazrat Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH